Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer
- 32 Downloads
After total mastectomy and partial axillary dissection, 805 premenopausal women with stage II breast cancer were randomized to receive postoperative radiotherapy (RT) alone, RT + cyclophosphamide (C) for 12 monthly cycles, or RT + cyclophosphamide/methotrexate/5-fluorouracil (CMF) for 12 monthly cycles. At 3 years actuarial relapse-free survival for RT + C and RT + CMF was significantly better than for RT alone (p = 0.0009 and 0.0001, respectively). There was no significant difference in relapse-free survival between RT + C and RT + CMF.
C resulted in more pronounced haematologic toxicity and a higher frequency of amenorrhoea and of alopecia than CMF, while CMF resulted in more pronounced nausea and stomatitis than C.
In the preliminary results, C alone may be as effective as CMF in prolonging relapse-free survival in premenopausal women with stage II breast cancer.
Keywordsadjuvant therapy breast cancer CMF cyclophosphamide
Unable to display preview. Download preview PDF.
- 1.Biran S, Brufman G, Robinson E, Borovik R, Brenner H, Rath P: Adjuvant radiotherapy with and without chemotherapy for stage II breast cancer: A national randomized study (abstract). Proc Am Soc Clin Oncol 1982, p. 83Google Scholar
- 2.Fisher B, Redmond C, Wolmark N, Wieand HS: Diseasefree survival at intervals during and following completion of adjuvant chemotherapy. Cancer 48:1271–1280, 1981Google Scholar
- 3.Howell A, Bush H, Howat J, Bramwell V, Harland RL, Crowther D, Sellwood RA: A controlled trial of adjuvant CMF and melphalan in patients with operable breast cancer (abstract). UICC Conference on Clinical Oncology, Lausanne, Switzerland, October 1981Google Scholar
- 5.Nissen-Meyer R: Chemotherapy and endocrine therapy of primary breast cancer. Reviews on Endocrine-Related Cancer, Suppl 6:71–82, 1980Google Scholar
- 6.Rossi A, Bonadonna G, Tancini G, Bajetta E, Marchini S, Valagussa P, Veronesi U: Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan.In HT Mouridsen and T Palshof (eds). Breast Cancer — Experimental and Clinical Aspects. Pergamon Press, Oxford, 1980, pp 149–156Google Scholar
- 7.Senn HJ, Amgwerd R, Junge WF: Adjuvant chemo (immuno) therapy with LMF + BCG in node-negative and node-positive breast cancer. 5-year results of a randomized study. Proc Am Soc Clin Oncol 22:426, 1981Google Scholar
- 8.Ahmann DL, Scanlon PW, Bisel HF, Edmonson HJ, Frytak S, Payne WS, O'Fallon JR, Hahn RJ, Ingle JN, O'Connel MJ, Rubin J: Repeated adjuvant chemotherapy with phenylalanine mustard, or 5-fluorouracil, cyclophosphamide and prednisone with or without radiation after mastectomy for breast cancer. Lancet 1:893–896, 1978PubMedGoogle Scholar
- 9.Glucksberg H, Rivkin S, Rasmussen S: Adjuvant chemotherapy for operable breast cancer with positive axillary nodes (abstract). Proc Am Soc Clin Oncol 22:426, 1981Google Scholar
- 12.Lee Y-TN, Sakulsky SB: Adjuvant chemotherapy (CMF) for breast carcinoma: Patient's compliance and total dose achieved (abstract). Proc Am Soc Clin Oncol 22:432, 1981Google Scholar
- 13.Glucksberg H, Rivkin SE, Rasmussen S: Adjuvant chemotherapy for stage II breast cancer: A comparison of CMFVP versus L-PAM.In SE Jones and SE Salmon (eds). Adjuvant Therapy of Cancer II. Grune and Stratton, New York, 1979, pp 261–268Google Scholar
- 15.Velez-Garcia E, Moore M, Marcial V, Bartolucci A, Ketcham A, Smalley R: Adjuvant chemotherapy and radiotherapy in stage II breast cancer (abstract). Proc Am Soc Clin Oncol 1982, p 80Google Scholar